Mira Pharmaceuticals Inc. has reported findings on the cognitive enhancing effects of MIRA-1a, an unscheduled novel synthetic tetrahydrocannabinol (THC) analogue, in normal mice.
The U.S. FDA 510(k) clearance of Airamed GmbH’s Airascore software could see millions of people benefitting from early accurate diagnosis of Alzheimer’s disease and other types of dementia. Airascore is a medical image management and processing system that uses deep learning and artificial intelligence (AI) to assess brain volumetry data on MRI scans in as little as five minutes.
With more drugs for Alzheimer’s disease (AD) gaining FDA approval and an aging population at increased risk of dementia, the need for AD diagnostics is only going to grow. An estimated 6.7 million Americans live with Alzheimer’s today, with that number projected to hit 14 million by 2060, according to the CDC.
The growing number of drugs gaining U.S. FDA approval for Alzheimer’s disease has kept their ability to reduce amyloid beta and tau proteins in the news, but the degenerative disease is not simply a matter of tangles and deposits. A loss of synaptic plasticity and disrupted neural networks underlie the signature impairment of memory and cognition – and those, researchers showed in a recent study in Brain, can be strengthened by non-invasive stimulation that addresses the brain’s electrical dysfunction.
As quicker, more accurate ways to detect dementia becomes ever more urgent, Cumulus Neuroscience Ltd. has teamed up with the Universities of Bath and Bristol in the U.K. to further develop the Fastball electroencephalogram (EEG) test, a diagnostic test for earlier detection of Alzheimer’s dementia. With one in three people born in the U.K. today likely to develop dementia at some point in their lives, early diagnosis and treatment are essential for them to plan for their future.
A group of international partners with expertise in therapeutics, technology, health data management and data science have joined forces to develop a range of digital tools that will predict and monitor dementia. The two-year pilot project launched in the U.K. will see the unique group focus their initial efforts on developing data and digital solutions to complement existing treatments as well as solving issues related to the prediction, prevention, management and treatment of dementia related disorders.
Regenlife SAS raised $3.3 million in series A funding in order to finalize the development of its photomodulation technology to treat neurodegenerative diseases.
The aqueous supernatants resulting from ultracentrifugation of brain samples from patients with Alzheimer’s disease (AD) contain aggregates so far described as soluble oligomers of amyloid-β protein (Aβ), which are responsible for the neurotoxicity underlying AD and thus considered targets to watch in this devastating condition. Now, a group of scientists from Harvard Medical School have determined that these aggregates are in fact insoluble diffusible fibrils with the same atomic structure as plaque fibrils.
Briefing documents suggest smooth sailing for Rexulti (brexpiprazole) at the meeting to deliberate an application to expand the label of the compound from Otsuka Pharmaceutical Co. Ltd. and Lundbeck A/S into agitation related to Alzheimer’s disease (AD) dementia. A joint sit-down on April 14 of the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee (adcom) and the Peripheral and Central Nervous System Drugs Advisory Committee will take up the matter of an add-on indication for Rexulti, a serotonin-dopamine activity modulator for schizophrenia and for the adjunctive treatment of major depressive disorder.
